Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
RGEN

RGEN - Repligen Corp Stock Price, Fair Value and News

$160.12-3.51 (-2.15%)
Market Closed

24/100

RGEN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

24/100

RGEN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$129.86

Target 3M

$146.1

Target 6M

$137.98

RGEN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

RGEN Price Action

Last 7 days

-5.8%

Last 30 days

-3.4%

Last 90 days

10.8%

Trailing 12 Months

-8.1%

RGEN RSI Chart

RGEN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

RGEN Valuation

Market Cap

9.0B

Price/Earnings (Trailing)

5.2K

Price/Sales (Trailing)

12.73

EV/EBITDA

107.58

Price/Free Cashflow

81.95

RGEN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$129.86

Target 3M

$146.1

Target 6M

$137.98

RGEN Fundamentals

RGEN Revenue

Revenue (TTM)

707.9M

Rev. Growth (Yr)

21.91%

Rev. Growth (Qtr)

3.53%

RGEN Earnings

Earnings (TTM)

1.7M

Earnings Growth (Yr)

2.4K%

Earnings Growth (Qtr)

0.3%

RGEN Profitability

EBT Margin

0.66%

Return on Equity

0.08%

Return on Assets

0.06%

Free Cashflow Yield

1.22%

RGEN Investor Care

Shares Dilution (1Y)

0.47%

Diluted EPS (TTM)

0.01

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025650.4M674.0M707.9M0
2024620.2M619.8M633.5M634.4M
2023760.5M712.1M652.5M632.4M
2022734.1M778.8M801.3M801.5M
2021433.0M508.5M592.7M670.5M
2020285.7M302.5M327.1M366.3M
2019209.8M232.8M252.7M270.2M
2018155.5M170.8M183.7M194.0M
2017110.0M113.3M125.2M141.2M
201687.8M95.5M100.4M104.5M
201566.9M72.8M77.5M83.5M
201466.0M64.1M60.4M60.4M
201365.9M67.9M71.6M68.2M
201236.3M44.1M50.6M62.3M
201127.3M27.9M29.3M29.4M
201000025.7M
Get all data in R, Python etc through our Historical Stock Data APIs

About Repligen Corp

RGEN
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
 CEO
 WEBSITErepligen.com
 SECTORHealthcare
 INDUSTRYMedical Instruments & Supplies
 EMPLOYEES2025

Repligen Corp Frequently Asked Questions

RGEN is the stock ticker symbol of Repligen Corp. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Repligen Corp is 9.01 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check RGEN's fair value in chart for subscribers.

The fair value guage provides a quick view whether RGEN is over valued or under valued. Whether Repligen Corp is cheap or expensive depends on the assumptions which impact Repligen Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RGEN.

As of Wed Jan 28 2026, RGEN's PE ratio (Price to Earnings) is 5.19 Thousand and Price to Sales (PS) ratio is 12.73. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RGEN PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Repligen Corp has provided 0.219 (multiply by 100 for percentage) rate of return.